The PISCES (Prevention of Cardiovascular Events in Hemodialysis Patients) trial, a large-scale international collaborative effort, enrolled 1,228 participants across 26 clinical sites located in both Australia and Canada, meticulously documenting their health outcomes over a defined period. The groundbreaking results of this rigorous study were formally presented at the esteemed American Society of Nephrology Kidney Week 2025 and subsequently published in the prestigious medical journal, The New England Journal of Medicine, underscoring the study’s scientific merit and significance within the global medical community.
At the heart of the PISCES trial’s success lies the intervention involving a daily dosage of four grams of a fish oil-derived supplement, rich in the essential omega-3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Participants who consistently adhered to this regimen exhibited a statistically significant reduction in the occurrence of major adverse cardiovascular events when contrasted with a control group receiving a placebo. This observed protective effect translates to a remarkable 43 percent decrease in the rate of these critical health emergencies. The spectrum of serious cardiovascular events encompassed within this substantial risk reduction includes fatal myocardial infarctions (heart attacks), cerebrovascular accidents (strokes), cardiac-related mortality, and vascular complications necessitating limb amputation.
The Australian arm of the PISCES trial was spearheaded by Adjunct Professor Kevan Polkinghorne, a distinguished nephrologist affiliated with Monash Health and an academic within the School of Clinical Sciences at Monash University. Professor Polkinghorne articulated the profound implications of these findings, stating that individuals undergoing dialysis face an extraordinarily elevated risk of cardiovascular disease, a challenge for which effective preventive strategies have historically been scarce. He further emphasized the rarity of positive outcomes in trials focused on this high-risk cohort, characterizing the PISCES results as a monumental achievement in a field often marked by negative or inconclusive findings.
A critical insight offered by Professor Polkinghorne pertains to the physiological state of dialysis patients, who often present with demonstrably lower endogenous levels of EPA and DHA compared to the general population. This deficiency, he posits, may serve as a key factor in elucidating the magnitude of the therapeutic benefit observed with omega-3 supplementation. By replenishing these vital fatty acids, the intervention appears to address a fundamental metabolic vulnerability inherent in chronic kidney disease patients.
It is imperative to underscore the specific applicability of the PISCES trial’s findings, as highlighted by Professor Polkinghorne, who stressed that the conclusions are strictly relevant to individuals undergoing hemodialysis as a treatment for kidney failure. The study’s design and participant characteristics necessitate caution against extrapolating these results to healthy individuals or to other patient groups with different underlying health conditions or treatment modalities. This precise delimitation ensures accurate interpretation and responsible clinical application of the research.
The execution of the Australian component of the PISCES study benefited from substantial financial and logistical support provided by the National Health and Medical Research Council (NHMRC), a leading governmental body dedicated to advancing health and medical research. Furthermore, the intricate coordination of the trial activities within Australia was expertly managed by the Australasian Kidney Trials Network (AKTN), an organization committed to facilitating high-quality clinical research in nephrology. Approximately 200 Australian participants contributed to the study’s data, with 44 of these individuals receiving treatment and care at Monash Health, underscoring the institution’s significant role in this international endeavor.
The global leadership and direction of the PISCES trial were jointly provided by Professor Charmaine Lok and her esteemed colleagues from the University Health Network in Toronto and the University of Calgary, demonstrating a powerful transatlantic collaboration in addressing a critical global health issue. Their visionary guidance was instrumental in the successful recruitment, execution, and analysis of this complex, multi-center research project. The trial’s design incorporated rigorous methodologies to ensure the reliability and validity of its outcomes, employing standardized protocols across all participating sites to maintain data integrity.
The pathogenesis of cardiovascular disease in end-stage renal disease is multifactorial, involving a complex interplay of traditional cardiovascular risk factors, such as hypertension and diabetes, alongside uremia-specific complications. These uremic complications can include endothelial dysfunction, increased inflammation, oxidative stress, and dyslipidemia, all of which contribute to accelerated atherosclerosis and a heightened risk of thrombotic events. The low levels of EPA and DHA observed in dialysis patients are believed to exacerbate these processes. EPA and DHA are known to exert pleiotropic effects on cardiovascular health, including anti-inflammatory, anti-arrhythmic, anti-thrombotic, and lipid-modulating properties. They can influence cell membrane fluidity, modulate inflammatory cytokine production, inhibit platelet aggregation, and improve endothelial function.
The PISCES trial represents a significant advancement in the management of cardiovascular risk in a particularly vulnerable patient population. While statins and other lipid-lowering agents have shown benefit in the general population, their efficacy in dialysis patients has been less consistent, highlighting the need for alternative or adjunctive therapies. The robust reduction in major adverse cardiovascular events observed with omega-3 supplementation suggests that targeting inflammatory pathways and improving lipid profiles through EPA and DHA may be a particularly effective strategy for this group.
Future research may explore optimal dosing strategies, long-term adherence, and the potential for personalized medicine approaches to omega-3 supplementation in dialysis patients. Furthermore, investigations into the specific mechanisms by which EPA and DHA exert their protective effects in this context could lead to the development of even more targeted and effective interventions. The PISCES trial’s findings not only provide a tangible benefit for current dialysis patients but also pave the way for a deeper understanding of cardiovascular pathophysiology in chronic kidney disease and the development of novel therapeutic strategies for preventing cardiovascular morbidity and mortality in this high-risk group. The consistent and substantial reduction in cardiovascular events observed in the PISCES trial offers a beacon of hope and a concrete, evidence-based recommendation for improving the quality of life and longevity for individuals grappling with kidney failure and the associated cardiovascular burden.
About the Author
